Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.

4 Nevertheless, in the subsequent Keynote-240 trial, both the median progression-free survival (PFS) and overall survival (OS) of pembrolizumab did not reach statistical significance per specified criteria. 5 Recently, atezolizumab (an anti-PD-L1-antibody) in combination with bevacizumab was approved for first-line treatment of advanced HCC based on results from the IMbrave150 trial, which demonstrated an impressive objective response rate (ORR) of 27.3%, median PFS of 6.8 months and OS at 12 months of 67.2%, all superior to the sorafenib arm. 6 Based on these emerging data, ICIs will be increasingly used in both first-line and second-line settings for the treatment of patients with advanced HCC.

also in 111,027 other papers